| 12.67 0.06 (0.48%) | 02-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.95 | 1-year : | 19.38 |
| Resists | First : | 14.51 | Second : | 16.6 |
| Pivot price | 13.37  |
|||
| Supports | First : | 11.13 | Second : | 9.26 |
| MAs | MA(5) : | 12.53 |
MA(20) : | 13.88 |
| MA(100) : | 12.87 |
MA(250) : | 0 | |
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 32.6 |
D(3) : | 29.8 |
| RSI | RSI(14): 44.2 |
|||
| 52-week | High : | 19.57 | Low : | 4.88 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AARD ] has closed above bottom band by 33.1%. Bollinger Bands are 13.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.74 - 12.8 | 12.8 - 12.86 |
| Low: | 11.85 - 11.92 | 11.92 - 11.98 |
| Close: | 12.56 - 12.67 | 12.67 - 12.77 |
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Fri, 12 Dec 2025
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 - Investing.com
Tue, 16 Sep 2025
Aardvark therapeutics CEO Lee Tien-Li buys $96,623 in shares - Investing.com
Fri, 12 Sep 2025
Aardvark therapeutics CEO Lee Tien-Li buys $160k in AARD - Investing.com
Fri, 14 Mar 2025
Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 14.5 (%) |
| Held by Institutions | 53.9 (%) |
| Shares Short | 1,620 (K) |
| Shares Short P.Month | 1,510 (K) |
| EPS | -2.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.63 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.9 % |
| Return on Equity (ttm) | -48.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -5.01 |
| PEG Ratio | 0 |
| Price to Book value | 2.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|